Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vericel Corporation - Common Stock (NQ:VCEL)

37.48 -1.08 (-2.80%)
Streaming Delayed Price Updated: 10:04 AM EST, Jan 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vericel Corporation - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Vericel to Present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026
From Vericel Corporation
Via GlobeNewswire
VERICEL CORP (NASDAQ:VCEL) Fits the "Growth at a Reasonable Price" Profile ↗
Via Chartmill
News headline image
Vericel Corp. (NASDAQ:VCEL) Presents a High-Growth Profile with a Technical Setup for a Potential Breakout ↗
Vericel Corp. (VCEL) combines strong revenue growth and accelerating earnings with a technical setup suggesting a potential price breakout from a key support level. 
Via Chartmill
News headline image
Vericel Corp (NASDAQ:VCEL) Emerges as a Top GARP Investment Candidate ↗
Vericel Corp (VCEL) exemplifies GARP investing with strong growth, high profitability, and a valuation reasonable for its biotech sector. 
Via Chartmill
News headline image
Vericel to Present at the Stephens Annual Investment Conference on Thursday, November 20, 2025
From Vericel Corporation
Via GlobeNewswire
News headline image
Earnings Scheduled For November 6, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For July 31, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 8, 2025 ↗
 
Via Benzinga
News headline image
Vericel Corp (NASDAQ:VCEL) Emerges as a Top Affordable Growth Candidate ↗
Vericel (VCEL) offers affordable growth in biotech with strong revenue & earnings, solid financials, and a reasonable valuation relative to peers. 
Via Chartmill
News headline image
Brown Capital Discloses $31 Million Sale of Vericel Stock as Small-Cap Biotech Reports Earnings ↗
Brown Capital Discloses $31 Million Sale of Vericel Stock as Small-Cap Biotech Reports Earnings 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Vericel (VCEL) Q3 2025 Earnings Call Transcript ↗
Vericel (VCEL) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Vericel Corporation (NASDAQ:VCEL) Surpasses Earnings Estimates with Strong Q3 2025 Results ↗
Vericel (VCEL) beats Q3 2025 earnings estimates with strong revenue growth and a swing to profitability, driven by its MACI and burn care products. 
Via Chartmill
News headline image
Vericel Reports Third Quarter 2025 Financial Results
From Vericel Corporation
Via GlobeNewswire
News headline image
Vericel Corp (NASDAQ:VCEL) Presents a Compelling Growth and Technical Setup ↗
Vericel (VCEL) combines strong revenue & earnings growth with a bullish technical setup, making it a top biotech growth stock to watch. 
Via Chartmill
News headline image
Vericel to Report Third-Quarter 2025 Financial Results on November 6, 2025
From Vericel Corporation
Via GlobeNewswire
News headline image
This FedEx Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday ↗
 
Via Benzinga
News headline image
Vericel to Present at the Wells Fargo Healthcare Conference on Thursday, September 4, 2025
From Vericel Corporation
Via GlobeNewswire
News headline image
MediWound Revenue Jumps 43% in Q2 ↗
Via The Motley Fool
News headline image
Vericel Corp (NASDAQ:VCEL): A High-Growth Stock with a Promising Technical Setup ↗
Vericel Corp (VCEL) is a high-growth biotech stock with strong fundamentals and a promising technical setup, making it a potential breakout candidate for investors. 
Via Chartmill
News headline image
Vericel Q2 Revenue Jumps 20% ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Vericel Corp (NASDAQ: VCEL) Posts Mixed Q2 2025 Results with Revenue Miss and EPS Beat ↗
Vericel Corp (VCEL) posted mixed Q2 2025 results with revenue missing estimates but EPS beating expectations. Shares fell 6.5% pre-market despite strong MACI growth and margin expansion. 
Via Chartmill
News headline image
Vericel Reports Second Quarter 2025 Financial Results
From Vericel Corporation
Via GlobeNewswire
News headline image
Vericel to Report Second-Quarter 2025 Financial Results on July 31, 2025
From Vericel Corporation
Via GlobeNewswire
News headline image
VERICEL CORP (NASDAQ:VCEL) – A Strong Growth Stock with Technical Breakout Potential ↗
VERICEL CORP (NASDAQ:VCEL) shows strong growth fundamentals and a technical breakout pattern, making it a stock to watch in the biotech sector. 
Via Chartmill
News headline image
Vericel to Present at the Truist Securities MedTech Conference on Tuesday, June 17, 2025
From Vericel Corporation
Via GlobeNewswire
News headline image
VERICEL CORP (NASDAQ:VCEL) – A Strong Growth Stock with Technical Breakout Potential ↗
VERICEL CORP (NASDAQ:VCEL) shows strong revenue and earnings growth, backed by a solid balance sheet and a promising technical breakout pattern. 
Via Chartmill
News headline image
What Analysts Are Saying About Vericel Stock ↗
 
Via Benzinga
News headline image
VERICEL CORP (NASDAQ:VCEL) – A Strong Growth Stock with a Technical Setup ↗
VERICEL CORP (NASDAQ:VCEL) shows strong growth potential with solid profitability and a promising technical setup, making it a stock worth watching. 
Via Chartmill
News headline image
Vericel Reports First Quarter 2025 Financial Results and Raises Full-Year Profitability Guidance
From Vericel Corporation
Via GlobeNewswire
News headline image
Vericel to Present at the Bank of America Securities 2025 Healthcare Conference on Wednesday, May 14, 2025
From Vericel Corporation
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.